PR Newswire
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
📈
AI Sentiment
Highly Positive
9/10
- Home
- NRSN
as of 01-22-2026 10:35am EST
$0.97
+$0.00
+0.02%
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
| Founded: | 2017 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 26.4M | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 320.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $2.60 | Next Earning Date: | 04-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NeuroSense Therapeutics Ltd. News
NRSN Breaking Stock News: Dive into NRSN Ticker-Specific Updates for Smart Investing
Compare NRSN vs Leading Stocks
See how NRSN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NRSN NeuroSense Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.